We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Andrew Fintel
Apr 07, 2015
We chose to treat this patient with Cyberknife radiation which she tolerated well. Although no randomized prospective trials exist in regards to systemic treatment following metastasectomy, we decided to offer her systemic therapy given that she is young and that there are restrospective studies showing improved progression free survival benefit. No overall survival benefit is known at this time for systemic therapy in this situation.
Eric Wiedower
Apr 14, 2015
Which systemic therapy did you offer? The case had stated that she was working as a nurse at time of diagnosis. If she had insisted on working, I would consider pazopanib based on the more favorable QOL measures and noninferior PFS when compared to sunitinib. Does the retrospective data favor one targeted agent in this setting?
Andrew Fintel
Apr 21, 2015
We chose to treat her with Sunitinib. If she had more extensive metastases then and not just the one site of relapse that was able to be treated by local Cyberknife then I believe pazapanib may be a better choice for the reasons you listed above. At the time of this patients treatment, Sunitinib was being used extrapolating data from Adjuvant trials, but now based on the ASSURE trial there is no role for adjuvant Sunitinib.
Nov 16, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Andrew Fintel
Apr 07, 2015
Eric Wiedower
Apr 14, 2015
Andrew Fintel
Apr 21, 2015
Nov 16, 2024
Pending Moderator approval.